A1 adenosine receptor antagonists

Details A1 adenosine receptor antagonists A1 adenosine receptor antagonists

2007-03-23

2008-09-09

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S263350, C514S263360, C514S263210, C514S263220, C514S263230, C514S263340, C544S267000, C544S269000, C544S270000, C544S272000, C544S273000

Reexamination Certificate

active

07423041

ABSTRACT:
Compounds of the general formula (I) are described:wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described.

REFERENCES:
patent: 2840559 (1958-06-01), Krantz, Jr. et al.
patent: 2887486 (1959-05-01), Leake et al.
patent: 3031451 (1962-04-01), Schlesinger et al.
patent: 3309271 (1967-03-01), Georges et al.
patent: 3317533 (1967-05-01), De Ridder
patent: 3961060 (1976-06-01), Fuxe
patent: 4092417 (1978-05-01), Credner et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4378359 (1983-03-01), Chiodoni et al.
patent: 4548818 (1985-10-01), Kjellin et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4622324 (1986-11-01), Klessing et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4769377 (1988-09-01), Snyder et al.
patent: 4772607 (1988-09-01), Badger et al.
patent: 4868186 (1989-09-01), Franzone et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 4971972 (1990-11-01), Doll et al.
patent: 5032593 (1991-07-01), Rzeszotarski et al.
patent: 5066655 (1991-11-01), Olsson
patent: 5068236 (1991-11-01), Suzuki et al.
patent: 5208240 (1993-05-01), Peet et al.
patent: 5248770 (1993-09-01), Jacobson et al.
patent: 5256650 (1993-10-01), Peet et al.
patent: 5290782 (1994-03-01), Suzuki et al.
patent: 5296463 (1994-03-01), Lee et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5314890 (1994-05-01), Agostini et al.
patent: 5340813 (1994-08-01), Klein et al.
patent: 5395836 (1995-03-01), Shimada et al.
patent: 5434150 (1995-07-01), Austel et al.
patent: 5447933 (1995-09-01), Suzuki et al.
patent: 5504090 (1996-04-01), Neely
patent: 5532368 (1996-07-01), Kufner-Muhl et al.
patent: 5543415 (1996-08-01), Suzuki et al.
patent: 5545627 (1996-08-01), Jacobson et al.
patent: 5714494 (1998-02-01), Connell et al.
patent: 5719279 (1998-02-01), Kufner-Muhl et al.
patent: 5733916 (1998-03-01), Neely
patent: 5739331 (1998-04-01), Thyrion et al.
patent: 5786360 (1998-07-01), Neely
patent: 5932557 (1999-08-01), Mustafa et al.
patent: 6001842 (1999-12-01), Neely
patent: 6117445 (2000-09-01), Neely
patent: 2002/0082269 (2002-06-01), Neely
patent: 2002/0111333 (2002-08-01), Lin et al.
patent: 2003/0212082 (2003-11-01), Linden et al.
patent: 2004/0014766 (2004-01-01), Dunten et al.
patent: 2004/0110774 (2004-06-01), Wilson
patent: 2005/0187226 (2005-08-01), Wilson et al.
patent: 636 828 (1964-03-01), None
patent: 1 245 383 (1967-07-01), None
patent: 26 59 241 (1978-07-01), None
patent: 0 501 379 (1992-09-01), None
patent: 0 503 563 (1992-09-01), None
patent: 0 764 647 (1997-03-01), None
patent: 2 483 922 (1981-11-01), None
patent: 947495 (1964-01-01), None
patent: 9216883 (1997-08-01), None
patent: WO 98/03507 (1998-01-01), None
patent: WO 99/67239 (1999-12-01), None
patent: WO 01/34610 (2001-05-01), None
patent: WO 03/028730 (2003-04-01), None
patent: WO 2004/074247 (2004-09-01), None
patent: WO 2004/110379 (2004-12-01), None
patent: WO 2004110379 (2004-12-01), None
Abbracchio, M.P. and F. Cattabeni, “Selective Activity of Bamifylline on Adenosine A1-receptors in Rat Brain,”Pharmacological Research Communications, 1987, pp. 537-545, vol. 19(8).
Ali, et al., “Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Edenosine A1Receptor,”The Journal of Pharmacology and Experimental Therapeutics, 1993, pp. 1328-1334, vol. 268(3).
Angulo, et al., “A1Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation,”Brain Pathol. 2003, pp. 440-451.
Aslanian, et al., “Cardiovascular and Pulmonary Diseases,”Annual Reports in Medicinal Chemistry, 2001, pp. 32-40, vol. 36(II), Academic Press, San Diego, CA.
Ball, et al., “Clinical Potential of Respirable Antisense Oligonucleotides (RASONs) in Asthma,”Am. J. Pharmacogenomics, 2003, pp. 97-106, vol. 3(2).
Beauglehole, et al., New Irreversible Adenosine A1Antagonists Based on FSCPX,Bioorganic and Medicinal Chemistry Letters, 2002, pp. 3179-3182, vol. 12.
Beauglehole, et al., Fluorosulfonyl-Substituted Xanthines as Selective Irreversible Antagonists for the A1Adenosine Receptor,J. Med. Chem., 2000, pp. 4973-4980, vol. 43.
Belardinelli, et al., 1, 3-Dipropyl-8-[2-(5, 6-Epoxy) Norbornyl]Xanthine, a Potent Specific and Selective A1Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT1MF-2 Cells,The Journal of Pharmacology and Experimental Therapeutics, 1995, pp. 1167-1176, vol. 276(2).
Belliardo, F. and C. Lucarelli, “Micro-Scale Liquid Chromatographic Method for the Determination of Bamifylline and its Major Metabolite in Human Plasma,”Journal of Chromatography, 1990, pp. 305-309, vol. 535.
Berti, et al., “Pharmacological Activity of Bamifylline on Lung Anaphylaxis: In Vitro Studies,”Pharmacological Research, 1990, vol. 22(2).
Carlucci, G., et al., “Determination of Bamifylline Hydrochloride Impurities in Bulk Material and Pharmaceutical Forms Using Liquid Chromatography with Ultraviolet Detection,”Journal of Pharmaceutical&Biomedical Analysis, 1990, pp. 1067-1069, vol. 8.
Cronstein, et al., “Neutrophil Adherence to Endothelium is Enhanced Via Adenosine A1Receptors and Inhibited Via Adenosine A2Receptors,”The Journal of Immunology, 1992, pp. 2201-2206, vol. 148.
Cronstein, et al., “The Adenosine/Neutrophil Paradox Resolved: Human Neutrophils Possess Both A1 and A2 Receptors that Promote Chemotaxis and Inhibit O2Generation, Respectively,”J. Clinic. Invest., 1990, pp. 1150-1157, vol. 85.
Dar, M.S. et al., “Acute Ethanol / Cannabinoid-Induced Ataxia and Its Antagonism by Oral/Systemic/Intracerebellar A1Adenosine Receptor Antisense in Mice,”Brain Research, 2002, pp. 53-60, vol. 957.
Foley, L.H. et al., “Modified 3-Alkyl-1, 8-dibenzylxanthines as GTP-Competitive Inhibitors of Phosphoenolpyruvate Carboxykinase,”Bioorganic&Medicinal Chemistry Letters, 2003, pp. 3607-3610, vol. 13.
Forman, et al., “Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil Chemotractant Reponse,”The Journal of Pharmacology and Experimental Therapeutics, 2000, pp. 929-938, vol. 292(3).
Gaspardone, et al., “Bamiphylline Improves Exercise-Induced Myocardial Ischemia Through a Novel Mechanism of Action,”Circulation, 1993, pp. 502-508, vol. 88(2).
Gaubert, Yves, “Clinical Experience with a New Antispasmodic,”Journal De Medicine De Bordeaux, May 1967, pp. 772-776, vol. 5.
Gottlieb, S.S., et al., “BG9719 (CVT-124), an A1Adenosine Receptor antagonist, Protects Against the Decline in Renal Function Observed with Diurectic Therapy,”Journal of American Heart Association, 2002, pp. 1348-1353.
Hess, S., “Recent Advances in Adenosine Receptor Antagonist Research,”Expert Opinion, Ashley Publications, 2001, pp. 1354-3776.
Jacobson, K.A., et al., “A Funcationalized Congener Approach to Adenosine Receptor Antagonists: Amino Acid Conjugates of 1,3-Dipropylxanthine,”Molecular Pharmacology, 1985, pp. 126-133, vol. 29.
Jacobson, K.A., et al., “Electrophilic Derivatives of Purines as Irreversible Inhibitors of A1Adenosine Receptors,”Journal of Medicinal Chemistry, 1989, pp. 1043-1051, vol. 32.
Jacobson, K.A., et al., “Molecular Probes for Extracellular Adenosine Receptors,”Biochemical Pharmacology, 1987, pp. 1697-1707, vol. 36(10).
Jacobson, et al., “Adenosine Receptors:Pharmacology, Structure-Activity Relationships, and Therapeutic Potential,”Journal of Medicinal Chemistry, 1992, pp. 407-422, vol. 35(3).
Kuroda, et al., Design, Synthesis and Biological Evaluation of a Novel Series of Potent, Orally Active Adenosine A1Receptor Antagonists with High Bloo

Affiliated with

Also associated with

Rating

A1 adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A1 adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A1 adenosine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3979157